The <scp> <i>IKZF1</i> N159S </scp> mutation is associated with poor outcome and a distinct molecular profile in adult patients with <scp>AML</scp>

IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the molecular and clinical associations of IKZF1 N159S-mutated AML, we performed a pooled analysis of 4136 AML patients. IKZF1 N159 mutations were found in 39 patients (0.94%) in a dominant clonal constellation, indicating early genetic events. N159S mutations were associated with aberrant karyotype, significantly higher rates of myelodysplasia-related gene mutations, ELN2022 adverse risk and a particularly poor outcome, supporting the classification of IKZF1 N159S-mutated AML as a rare molecular subtype with adverse prognosis.

Authors

Institutions

Publication Details

Journal
British Journal of Haematology
Published
2025-03-05
DOI
https://doi.org/10.1111/bjh.20027
Citations
3
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
5.31
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML

Johannes Schetelig, Christian Thiede, Sebastian Stasik, Gerhard Ehninger et al.
3 citations
British Journal of Haematology
Acute Myeloid Leukemia Research
5.31
article

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML

Johannes Schetelig, Christian Thiede, Sebastian Stasik, Gerhard Ehninger, Christoph Röllig, Martin Bornhäuser, Jan‐Niklas Eckardt, Carsten Müller‐Tidow, Claudia Dorothea Baldus, Jan Moritz Middeke, Andreas Neubauer, Mathias Hänel, Uwe Platzbecker, Stefan W. Krause, Hubert Serve, Tim Sauer, Martin Kaufmann, Kerstin Schäfer‐Eckart
article en
3 citations

Abstract

IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the molecular and clinical associations of IKZF1 N159S-mutated AML, we performed a pooled analysis of 4136 AML patients. IKZF1 N159 mutations were found in 39 patients (0.94%) in a dominant clonal constellation, indicating early genetic events. N159S mutations were associated with aberrant karyotype, significantly higher rates of myelodysplasia-related gene mutations, ELN2022 adverse risk and a particularly poor outcome, supporting the classification of IKZF1 N159S-mutated AML as a rare molecular subtype with adverse prognosis.

British Journal of HaematologyVol. 206(5)
Goethe University Frankfurt (DE), Philipps University of Marburg (DE), Heidelberg University (DE), University Hospital Heidelberg (DE), Robert Bosch Hospital (DE), Universitätsklinikum Erlangen (DE), Nuremberg Hospital (DE), Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie (DE), National Center for Tumor Diseases (DE), University Hospital Schleswig-Holstein (DE), University Hospital Leipzig (DE), University Hospital Frankfurt (DE), University Hospital Carl Gustav Carus (DE), Klinikum Chemnitz (DE), Deutsche Knochenmarkspenderdatei (DE), Klinik und Poliklinik für Psychotherapie und Psychosomatik (DE), University of Lübeck (DE)
No poverty
Openalex Percentile: Top 5%
Acute Myeloid Leukemia Research
5.31
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.